These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 34503206)

  • 1. Neoadjuvant Treatment for Pancreatic Adenocarcinoma: A False Promise or an Opportunity to Improve Outcome?
    Khakoo S; Petrillo A; Salati M; Muhith A; Evangelista J; Seghezzi S; Petrelli F; Tomasello G; Ghidini M
    Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer.
    Janssen QP; O'Reilly EM; van Eijck CHJ; Groot Koerkamp B
    Front Oncol; 2020; 10():41. PubMed ID: 32083002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
    Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
    Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan.
    Ei S; Takahashi S; Ogasawara T; Mashiko T; Masuoka Y; Nakagohri T
    Gut Liver; 2023 Sep; 17(5):698-710. PubMed ID: 36843421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study).
    Schwarz L; Vernerey D; Bachet JB; Tuech JJ; Portales F; Michel P; Cunha AS
    BMC Cancer; 2018 Jul; 18(1):762. PubMed ID: 30041614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant Chemotherapy in Pancreatic Cancer: An Appraisal of the Current High-Level Evidence.
    Müller PC; Frey MC; Ruzza CM; Nickel F; Jost C; Gwerder C; Hackert T; Z'graggen K; Kessler U
    Pharmacology; 2021; 106(3-4):143-153. PubMed ID: 32966993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Neoadjuvant treatment of primarily resectable and borderline resectable pancreatic cancer].
    Scheufele F; Friess H
    Chirurg; 2020 May; 91(5):391-395. PubMed ID: 31965198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial.
    Murphy JE; Wo JY; Ryan DP; Jiang W; Yeap BY; Drapek LC; Blaszkowsky LS; Kwak EL; Allen JN; Clark JW; Faris JE; Zhu AX; Goyal L; Lillemoe KD; DeLaney TF; Fernández-Del Castillo C; Ferrone CR; Hong TS
    JAMA Oncol; 2018 Jul; 4(7):963-969. PubMed ID: 29800971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neo-adjuvant therapy for pancreatic cancer: hope for the future.
    Borazanci E; Sckolnik S; Amini A
    Expert Rev Gastroenterol Hepatol; 2019 Jun; 13(6):579-589. PubMed ID: 30979348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Patient With Locally Advanced Mismatch-Repair-Deficient Pancreatic Ductal Adenocarcinoma Successfully Treated With Neoadjuvant Immunotherapy.
    Cox RE; Mahipal A; Chakrabarti S
    Cureus; 2021 Apr; 13(4):e14640. PubMed ID: 34055508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Borderline resectable pancreatic cancer.
    Hackert T; Ulrich A; Büchler MW
    Cancer Lett; 2016 Jun; 375(2):231-237. PubMed ID: 26970276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer.
    Slagter AE; Jansen EPM; van Laarhoven HWM; van Sandick JW; van Grieken NCT; Sikorska K; Cats A; Muller-Timmermans P; Hulshof MCCM; Boot H; Los M; Beerepoot LV; Peters FPJ; Hospers GAP; van Etten B; Hartgrink HH; van Berge Henegouwen MI; Nieuwenhuijzen GAP; van Hillegersberg R; van der Peet DL; Grabsch HI; Verheij M
    BMC Cancer; 2018 Sep; 18(1):877. PubMed ID: 30200910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of neoadjuvant radiotherapy on survival of non-metastatic pancreatic ductal adenocarcinoma: a SEER database analysis.
    Wang D; Liu C; Zhou Y; Yan T; Li C; Yang Q; Xu Y; Zhao L; Pei Q; Tan F; Güngör C; Li Y
    Radiat Oncol; 2020 May; 15(1):107. PubMed ID: 32404114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant and adjuvant chemotherapy in pancreatic cancer.
    Klaiber U; Leonhardt CS; Strobel O; Tjaden C; Hackert T; Neoptolemos JP
    Langenbecks Arch Surg; 2018 Dec; 403(8):917-932. PubMed ID: 30397779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Borderline resectable pancreatic cancer: Certainties and controversies.
    Nappo G; Donisi G; Zerbi A
    World J Gastrointest Surg; 2021 Jun; 13(6):516-528. PubMed ID: 34194610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in neoadjuvant therapy for resectable pancreatic cancer over the past two decades.
    Taboada AGM; Lominchar PL; Roman LM; García-Alfonso P; Martin AJM; Rodriguez JAB; Pascual JMA
    Ann Hepatobiliary Pancreat Surg; 2021 May; 25(2):179-191. PubMed ID: 34053920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surgery for Pancreatic Cancer after neoadjuvant treatment.
    Hackert T
    Ann Gastroenterol Surg; 2018 Nov; 2(6):413-418. PubMed ID: 30460344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study.
    Heinrich S; Besselink M; Moehler M; van Laethem JL; Ducreux M; Grimminger P; Mittler J; Lang H; Lutz MP; Lesurtel M;
    BMC Cancer; 2019 Jul; 19(1):675. PubMed ID: 31288786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of pancreatic cancer-neoadjuvant treatment in resectable pancreatic cancer (PDAC).
    Seufferlein T; Ettrich TJ
    Transl Gastroenterol Hepatol; 2019; 4():21. PubMed ID: 30976724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current view of neoadjuvant chemotherapy in primarily resectable pancreatic adenocarcinoma.
    Eid M; Ostřížková L; Kunovský L; Brančíková D; Kala Z; Hlavsa J; Janeček P; Kosíková I; Blažková M; Slabý O; Mayer J
    Neoplasma; 2021 Jan; 68(1):1-9. PubMed ID: 32880468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.